...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Psoriasis: Targets and Therapy >Long-term safety of biologics in the treatment of psoriasis
【24h】

Long-term safety of biologics in the treatment of psoriasis

机译：生物制剂在治疗牛皮癣中的长期安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Biologics are novel and important agents in the treatment of severe psoriasis. These agents block specific molecular steps in the inflammatory cascade, thereby reducing activation and proliferation of keratinocytes. Prescreening for biologic agents and careful monitoring of patients is important. There are four biologics currently licensed and used in the treatment of psoriasis in the European Union. This is an evidence-based review examining clinical trials and focusing on the long-term safety data for four biologic agents. Current British Association of Dermatology guidance for the use of biologics in psoriasis and guidelines on the management of psoriasis from the National Institute for Health and Clinical Excellence have been used. Advances on safety information since 2009 in clinical trials are reviewed. The results show that overall there is no statistical significance in the incidence of adverse effects of biologics versus placebo. However, there are serious adverse effects that are reported for biologics that need to be assessed for and addressed promptly. Results of studies discussing major adverse cardiovascular events are also reviewed.
机译：摘要：生物制剂是治疗严重牛皮癣的新型重要药物。这些试剂阻断了炎症级联反应中的特定分子步骤，从而减少了角质形成细胞的活化和增殖。对生物制剂进行预筛查和对患者进行仔细监测很重要。欧盟目前有四种许可用于牛皮癣治疗的生物制剂。这是一项循证审查，审查了临床试验，并着眼于四种生物制剂的长期安全性数据。目前，英国皮肤病学协会使用了牛皮癣中使用生物制剂的指南以及美国国立卫生与临床卓越研究所的牛皮癣管理指南。综述了自2009年以来在临床试验中安全信息的进展。结果表明，与安慰剂相比，生物制剂的不良反应发生率总体上没有统计学意义。但是，据报告，对于生物制剂存在严重的不良反应，需要对其进行评估和迅速解决。还讨论了讨论主要不良心血管事件的研究结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号